Biogen will acquire Antibody Transport Vehicle Program Targeting Amyloid Beta from Denali
Biogen Inc. and Denali Therapeutics Inc. announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Abeta). Accumulation of Abeta plaque in the brain is a defining feature of Alzheimer’s disease (AD)
Using Denali’s ATV platform to cross the blood-brain barrier (BBB), ATV: Abeta is designed to increase brain exposure and target engagement of antibody therapeutics directed against A, which may enable improved plaque clearance and/or reduced amyloid-related imaging abnormalities (ARIA). “Recent progress with A-directed therapeutic antibodies enables new treatment options for people living with AD, and clinical trial data have demonstrated that clearance of aggregated Abeta is associated with benefit for patients,” said Joseph Lewcock, Ph.D., Chief Scientific Officer of Denali. “Our ATV: Abeta program is designed to safely increase exposure of the therapeutic antibody in the brain and potentially lead to improved efficacy and/or safety. We are pleased with Biogen’s decision to license ATV: A and we are hopeful this will foster the development of next-generation anti- Abeta therapeutics.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
